SCHEMBL5877175

SCHEMBL5877175

C1=CC(c2ccccc2)Cc2[nH]nc(-c3cccnc3)c21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.45
LRRK2 Q5S007 1/20 0.45
ALPL P05186 1/20 0.41
PIM1 P11309 3/20 0.40
PIM2 Q9P1W9 2/20 0.40
PIM3 Q86V86 1/20 0.40
MAP2K4 P45985 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
AXL P30530 1/20 0.38
ALDH1A1 P00352 5/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
MAPK10 P53779 1/20 0.37
MAPK1 P28482 1/20 0.37
NPY5R Q15761 1/20 0.36
TTK P33981 1/20 0.36
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876644 0.88 MAPK10 (0.46) IDO1ALPLPIM1SMN1; SMN2ALDH1A1
SCHEMBL5877114 0.86 MKNK1 (0.40) PIM1LMNAMAPK10MAPK1HTR7
SCHEMBL5878102 0.80 IDO1 (0.42) IDO1LRRK2PIM1LMNAMAPK10
SCHEMBL5876901 0.79 LRRK2 (0.40) LRRK2ALPLPIM1PIM2PIM3
SCHEMBL5878068 0.78 PIM1 (0.40) IDO1LRRK2PIM1LMNAMAPK10
SCHEMBL5877207 0.78 HDAC4 (0.37) LRRK2PIM1ALDH1A1KDM4EMEN1
SCHEMBL5875946 0.78 ADORA2A (0.38) LMNAMAPK10NPY5RHTR7CYP2A6
SCHEMBL5875877 0.77 NISCH (0.41) PIM1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL5876657 0.76 HDAC4 (0.37) LMNAMAPK10HTR7CYP3A4
SCHEMBL5875924 0.75 HCAR2 (0.38) PIM1LMNAMAPK10HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT IDO1 1/4885LRRK2 1067/4885ALPL 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.